NIH RFA · NIAMS · P30
RFA-AR-28-001: NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The overall goal of this program is to accelerate scientific discovery, improve research efficiency, and enhance the translation of research findings into improved health outcomes. Centers funded under this program will also foster multidisciplinary collaboration, support workforce development across career stages, and promote training in emerging areas such as data science, artificial intelligence, and implementation research. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS P30 Centers Program to support integrated research Centers within its mission areas of skin biology and diseases; bone, muscle, and orthopaedic…
- NOFO number
- RFA-AR-28-001
- Type
- RFA
- Activity code
- P30
- Primary institute
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Clinical trials
- Not Allowed
- Posted
- Oct 9, 2026
- Opens
- Jan 1, 2027
- Expires
- Mar 2, 2029
RFA-AR-28-001 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 01, 2027 | March 01, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| February 01, 2028 | March 01, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| February 01, 2029 | March 01, 2029 | Not Applicable | July 2029 | October 2029 | December 2029 |
What its predecessor RFA-AR-23-002 funded
RFA-AR-28-001 reissues RFA-AR-23-002. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 3 projects and $9.4M in FY2022–FY2026.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
0
Type 1 (new project) award records
NIH funding
$9.4M
Award dollars under RFA-AR-23-002, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 3 | 0 | $2.4M |
| FY2024 | 3 | 0 | $2.4M |
| FY2025 | 3 | 0 | $2.2M |
| FY2026 | 3 | 0 | $2.4M |
Institutions with the most funding
- Oklahoma Medical Research Foundation$3.3M · 1 project
- Washington University$3.0M · 1 project
- Cincinnati Childrens Hosp Med Ctr$3.0M · 1 project
Funding institutes
- NIAMS$9.4M · 12
Activity codes funded
- P3012 records
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-AR-28-001. Contact the program officer at the institute that fits your research before applying.
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- ORWH
Related notices
Jan 23, 2026 · NOT-OD-26-031
NIH Pause on New Submissions to the NIH Human Embryonic Stem Cell Registry and Request for Information on Reducing Reliance on Human Embryonic Stem Cells in NIH-Supported Research.
Award terms
- Application types allowed
- New Renewal The OER Glossary and the How to Apply - Application Guide provides details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 500,000 direct costs per year.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- NIAMS intends to commit up to 17 million direct costs to fund up to 30 awards over the duration of this NOFO. Awards pursuant to this funding opportunity are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations.NIAMS intends to fund a minimum of one new center that has not yet…
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-AR-23-002.
Other open NOFOs for P30
- RFA-DK-27-120Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)NIDDK · next due Oct 20, 2026
- PAR-27-054Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed)NIGMS · next due Jan 25, 2027
- PAR-27-055Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed)NIGMS · next due Jan 25, 2027
- PAR-25-444Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)NCI · next due Jan 25, 2027
- RFA-DK-26-310Diabetes Research Centers (P30 Clinical Trial Optional)NIDDK · next due Jan 27, 2027
- PAR-27-056Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional)NIGMS · next due Jan 28, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.